Endothelin receptor antagonists

Endothelin receptor antagonists are medicines that block the receptors for endothelin-1, a peptide that acts on blood vessels. MeSH describes the group as compounds and drugs that bind to and block the activation of endothelin receptors. The US labels of Tracleer (bosentan), Letairis (ambrisentan) and Opsumit (macitentan) each call the product an endothelin receptor antagonist indicated for pulmonary arterial hypertension, and each medicine has its own page. This is the class page: what each medicine has been shown to do, and its warnings, sit on its own page.

Also called Endothelin Receptor Antagonist · Endothelin Antagonists · ERA

  • Drug
  • In this atlas

Overview

Technical summary

Class page. MeSH descriptor D065128 (Endothelin Receptor Antagonists, lastUpdated 2020-05-27) is an exact match; its scope note says these are compounds and drugs that bind to and inhibit or block the activation of endothelin receptors. RxClass lists, for each of bosentan, ambrisentan and macitentan, the established pharmacologic class on US drug labels Endothelin Receptor Antagonist (EPC) and the mechanism-of-action class Endothelin Receptor Antagonists (read 2026-11-18); the three medicines are filed under this page on that evidence. The Letairis label says endothelin-1 acts through two receptor subtypes, ET A and ET B, in vascular smooth muscle and the endothelium. The combination product that pairs macitentan with tadalafil was not read. No trial result, dose or instruction is recorded.

Drugs in this class

3 drugs in this atlas are filed under Endothelin receptor antagonists, with the registry trials and FDA regulatory decisions this atlas holds for each. With Endothelin receptor antagonists itself, the class has 0 distinct trials and 0 distinct FDA decisions; a trial or decision that two of them share counts once there.

About this drug

Level
Class
Mechanism
MeSH says these compounds and drugs bind to and block the activation of endothelin receptors; the Letairis label says endothelin-1 acts through the ET A and ET B receptor subtypes in the vascular smooth muscle and endothelium.

Claims and evidence

No claims are published for this drug yet.

Record details

Record id
cardio:endothelin-receptor-antagonists
Content hash
a83cb07c27e21b500fd5be00ff2d5a6d5c57edf1b393d634c3409c7dff9b0101